Compounds > adn 138

Page last updated: 2024-11-07

adn 138

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ADN 138: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	127323
CHEMBL ID	143895
SCHEMBL ID	10367313
MeSH ID	M0154184

Synonyms (13)

Synonym
adn 138
adn-138
CHEMBL143895
99434-90-9
8'-chloro-2',3'-dihydrospiro(pyrrolidine-3,6'(5'h)-pyrrolo(1,2,3-de)(1,4)benzoxazine)-2,5,5'-trione
spiro(pyrrolidine-3,6'(5'h)-pyrrolo(1,2,3-de)(1,4)benzoxazine)-2,5,5'-trione, 8'-chloro-2',3'-dihydro-
8'-chloro-2',3'-dihydrospiro[pyrrolidine-3,6'(5'h)-pyrrolo[1,2,3-de][1,4]benzoxazine]-2,5,5'-trione
WSLOHMLGIVSUPR-UHFFFAOYSA-N
SCHEMBL10367313
8-chloro-5'-hydroxy-2,3-dihydro-5h-spiro[1,4-oxazino[2,3,4-hi]indole-6,3'-pyrrole]-2',5(4'h)-dione
DTXSID00912710
6-chlorospiro[9-oxa-1-azatricyclo[6.3.1.04,12]dodeca-4(12),5,7-triene-3,3'-pyrrolidine]-2,2',5'-trione
AKOS040750148

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay ID	Title	Year	Journal	Article
AID181872	In vivo galactitol inhibitory activity measured by its ability to inhibit galactitol accumulation in sciatic nerve at 10 mg/kg/day	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents.
AID34355	In vitro aldose reductase inhibitory activity measured by NADPH-dependent inhibition of glyceraldehyde reduction in a partially purified bovine lens preparation at 10E-7 M	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents.
AID184345	In vivo galactitol inhibitory activity measured by its ability to inhibit galactitol accumulation in lens at 10 mg/Kg/day	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents.
AID184326	In vivo galactitol inhibitory activity measured by its ability to inhibit galactitol accumulation in diaphragm at 10 mg/kg/day	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents.
AID34354	In vitro aldose reductase inhibitory activity measured by NADPH-dependent inhibition of glyceraldehyde reduction in a partially purified bovine lens preparation at 10E-6 M	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	3 (60.00)	18.7374
1990's	2 (40.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	52.35 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.39 (4.65)
Search Engine Demand Index	79.51 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (52.35)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
inositol Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.	2.66	3	0	cyclitol; hexol
ciglitazone ciglitazone: structure given in second source; PPAR agonist used for type II diabetes. ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.	1.98	1	0	aromatic ether; thiazolidinone	antineoplastic agent; insulin-sensitizing drug
ponalrestat [no description available]	1.97	1	0	phthalazines
sorbitol D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).	2.37	2	0	glucitol	cathartic; Escherichia coli metabolite; food humectant; human metabolite; laxative; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite; sweetening agent
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.89	4	0	pyrrole; secondary amine
galactitol [no description available]	1.97	1	0	hexitol	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
tolrestat tolrestat: RN & structure given in first source	1.98	1	0	naphthalenes	EC 1.1.1.21 (aldehyde reductase) inhibitor
sorbinil sorbinil: aldose reductase inhibitor. sorbinil : An azaspiro compound having a monofluoro-substituted chromane skeleton spiro-linked to an imidazolidinedione ring.	2.38	2	0	azaspiro compound; chromanes; imidazolidinone; organofluorine compound; oxaspiro compound	antioxidant; EC 1.1.1.21 (aldehyde reductase) inhibitor
imidazolidines [no description available]	1.97	1	0	azacycloalkane; imidazolidines; saturated organic heteromonocyclic parent
bm 131246 [no description available]	1.98	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Alloxan Diabetes [description not available]	0	2.89	4	0
Cataract, Membranous [description not available]	0	2.37	2	0
Classic Galactosemia [description not available]	0	2.37	2	0
Cataract Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed)	0	2.37	2	0
Galactosemias A group of inherited enzyme deficiencies which feature elevations of GALACTOSE in the blood. This condition may be associated with deficiencies of GALACTOKINASE; UDPGLUCOSE-HEXOSE-1-PHOSPHATE URIDYLYLTRANSFERASE; or UDPGLUCOSE 4-EPIMERASE. The classic form is caused by UDPglucose-Hexose-1-Phosphate Uridylyltransferase deficiency, and presents in infancy with FAILURE TO THRIVE; VOMITING; and INTRACRANIAL HYPERTENSION. Affected individuals also may develop MENTAL RETARDATION; JAUNDICE; hepatosplenomegaly; ovarian failure (PRIMARY OVARIAN INSUFFICIENCY); and cataracts. (From Menkes, Textbook of Child Neurology, 5th ed, pp61-3)	0	2.37	2	0
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	0	1.97	1	0
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	0	1.97	1	0